LGVN Longeveron

Longeveron to Participate in Upcoming 2022 Investor Conferences

Longeveron to Participate in Upcoming 2022 Investor Conferences

MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that Company leadership will participate in three upcoming investor conferences.

A.G.P.’s Virtual Biotech Conference

Format: One-on-one Meetings

Date: Wednesday, November 30, 2022

Location: Virtual

The Benchmark Company 11th Annual Discovery One-on-One Investor Conference

Format: One-on-one Meetings

Date: Thursday, December 1, 2022

Location: New York, NY

RHK 2022 Disruptive Growth Conference

Format: Company Presentation

Date: Tuesday, December 6, 2022

Location: New York, NY

Time: 10:40-11:00 a.m. ET

A live webcast of the presentation at the RHK 2022 Disruptive Growth Conference can be accessed by visiting “Events & Presentations” in the Investors section of Longeveron’s website at . A replay of the webcast will be available shortly following the conference.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has a multi-modal mechanism of action that is pro-vascular, pro-regenerative, and anti-inflammatory, promoting tissue repair and healing with broad potential applications across a spectrum of disease areas. Longeveron is advancing Lomecel-B™ through clinical trials in three indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s Disease, and Aging Frailty. Additional information about the Company is available at .

Investor Contact:

Elsie Yau

Stern IR, Inc.

212-698-8700

Source: Longeveron Inc



EN
29/11/2022

Underlying

LGVNLongeveron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Announces Key Leadership Updates

Longeveron® Announces Key Leadership Updates Than Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa’el Hashad to step down as CEO and Board memberNational search to occur for permanent CEO MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced key leadership u...

September 3, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Inves...

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 in New York City. Details for the Company’s presentation:    Date:Monday, September 8, 2025 Time:4:00 – 4:30 p.m. ET    The webcast for this conf...

August 20, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Announces Second Quarter 2025 Financial Results and Provid...

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in late 2026, if ELPIS II results are positiveStem cell therapy pipeline expanded ...

August 13, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron Announces Closing Of Up To $17.5 Million Public Offering $5.0 million upfront with up to an additional $12.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced the closing of its previously announced public offering of 5,882,354 of the Company’s Class A c...

August 11, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron Announces Up To $17.5 Million Public Offering $5.0 million upfront with up to an additional $12.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced the pricing of a public offering of 5,882,354 of the Company’s Class A common stock (or pre-funded warrant...

August 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch